[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1093017A1 - Inhalable formulations for treating pulmonary hypertension and methods of using same - Google Patents

Inhalable formulations for treating pulmonary hypertension and methods of using same

Info

Publication number
HK1093017A1
HK1093017A1 HK06113768.7A HK06113768A HK1093017A1 HK 1093017 A1 HK1093017 A1 HK 1093017A1 HK 06113768 A HK06113768 A HK 06113768A HK 1093017 A1 HK1093017 A1 HK 1093017A1
Authority
HK
Hong Kong
Prior art keywords
pulmonary hypertension
methods
same
present
treating pulmonary
Prior art date
Application number
HK06113768.7A
Other languages
English (en)
Inventor
Imtiaz Chaudry
Original Assignee
Dey Pharma L P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dey Pharma L P filed Critical Dey Pharma L P
Publication of HK1093017A1 publication Critical patent/HK1093017A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK06113768.7A 2003-06-27 2006-12-14 Inhalable formulations for treating pulmonary hypertension and methods of using same HK1093017A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/609,233 US20040265238A1 (en) 2003-06-27 2003-06-27 Inhalable formulations for treating pulmonary hypertension and methods of using same
PCT/EP2004/006629 WO2005000270A2 (en) 2003-06-27 2004-06-18 Inhalable formulations for treating pulmonary hypertension and methods of using same

Publications (1)

Publication Number Publication Date
HK1093017A1 true HK1093017A1 (en) 2007-02-23

Family

ID=33540807

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06113768.7A HK1093017A1 (en) 2003-06-27 2006-12-14 Inhalable formulations for treating pulmonary hypertension and methods of using same

Country Status (16)

Country Link
US (3) US20040265238A1 (xx)
EP (1) EP1638525B1 (xx)
JP (3) JP5571867B2 (xx)
KR (3) KR20060026070A (xx)
CN (1) CN1822817B (xx)
AT (1) ATE548025T1 (xx)
AU (2) AU2004251014B8 (xx)
BR (1) BRPI0411904B8 (xx)
CA (1) CA2530632C (xx)
ES (1) ES2384384T3 (xx)
HK (1) HK1093017A1 (xx)
MX (1) MXPA05013539A (xx)
PL (1) PL1638525T3 (xx)
RU (2) RU2491072C2 (xx)
WO (1) WO2005000270A2 (xx)
ZA (1) ZA200600773B (xx)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120058618A (ko) * 2003-01-31 2012-06-07 다이이찌 산쿄 가부시키가이샤 동맥 경화 및 고혈압증의 예방 및 치료를 위한 의약
KR101187693B1 (ko) * 2003-05-09 2012-10-05 도레이 카부시키가이샤 신장질환의 치료 또는 예방제
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
CA2549724C (en) * 2003-12-16 2014-02-11 United Therapeutics Corporation Use of treprostinil to treat and prevent ischemic lesions
US20090124697A1 (en) 2003-12-16 2009-05-14 United Therapeutics Corporation Inhalation formulations of treprostinil
US7820817B2 (en) * 2004-05-28 2010-10-26 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US8431535B2 (en) * 2004-09-10 2013-04-30 Hoiberg A/S Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis
US7528175B2 (en) * 2004-10-08 2009-05-05 Inverseon, Inc. Method of treating airway diseases with beta-adrenergic inverse agonists
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
BRPI0612674B8 (pt) * 2005-06-27 2021-05-25 Daiichi Sankyo Co Ltd preparação farmacêutica, uso de um antagonista do receptor de angiotensina ii e um bloqueador do canal de cálcio
CA2625862A1 (en) * 2005-10-14 2007-04-26 Transform Pharmaceuticals, Inc. Liquid pharmaceutical compositions of nimodipine
CA2654492C (en) 2006-05-15 2017-06-27 United Therapeutics Corporation Treprostinil administration using a metered dose inhaler
WO2007140285A2 (en) * 2006-05-26 2007-12-06 Dey, L.P. Nebulizable compositions of quaternary ammonium muscarinic receptor antagonists
DE102006026786A1 (de) 2006-06-07 2007-12-13 Joachim Kern Dosierinhalator
WO2008002929A2 (en) * 2006-06-26 2008-01-03 Inverseon, Inc. Heterologous cross-sensitization for improved agonist activity
WO2008019106A1 (en) * 2006-08-04 2008-02-14 Artesian Therapeutics, Inc. Methods and compositions for the treatment of pulmonary hypertension using a combination of a calcium channel blocker and a phosphodiesterase inhibitor
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
WO2008149201A2 (en) * 2007-06-06 2008-12-11 Emcure Pharmaceuticals Limited Stable pharmaceutical composition
NZ583069A (en) * 2007-07-24 2012-06-29 Viridis Biopharma Pvt Ltd Treatments using vitamin k analogues and derivatives
CA2710349A1 (en) * 2007-12-27 2009-07-09 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide -donating compounds and uses thereof
US20120177693A1 (en) * 2008-09-25 2012-07-12 Aradigm Corporation Deep lung pulmonary delivery of treprostinil
CN102421288B (zh) * 2009-05-07 2015-04-22 联合治疗公司 前列环素类似物的固体剂型
CN101891596B (zh) * 2009-05-22 2013-12-11 上海天伟生物制药有限公司 一种化合物及其制备方法和用途
SG176738A1 (en) 2009-06-12 2012-01-30 Mannkind Corp Diketopiperazine microparticles with defined specific surface areas
EA023720B1 (ru) * 2009-08-07 2016-07-29 Сифарм Сарл Композиция для лечения муковисцидоза
CN103237446B (zh) 2010-10-12 2014-11-05 医药公司 含有抗微生物剂的氯维地平乳剂制剂
US8658676B2 (en) * 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
CN102580090A (zh) * 2011-01-06 2012-07-18 北京水圣木科技有限责任公司 一种用于治疗高血压的颗粒剂
GB201113662D0 (en) * 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
GB201217330D0 (en) * 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
US20140170158A1 (en) * 2012-12-17 2014-06-19 The Johns Hopkins University Compositions and methods for treating or preventing lung diseases
WO2014144895A1 (en) 2013-03-15 2014-09-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
AU2014290438B2 (en) 2013-07-18 2019-11-07 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
RU2559424C1 (ru) * 2014-06-18 2015-08-10 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения Российской Федерации (ФГБУ "РКНПК" Минздрава России) Способ подбора лекарственной терапии больным с идиопатической легочной гипертензией
RU2593016C2 (ru) * 2014-12-15 2016-07-27 Федеральное государственное бюджетное учреждение науки Институт теоретической и прикладной механики им. С.А. Христиановича Сибирского отделения Российской академии наук (ИТПМ СО РАН) Способ лечения артериальной гипертензии путем ингаляционного введения аэрозоля гипотензивного препарата
KR101938036B1 (ko) * 2015-04-16 2019-01-14 서울대학교산학협력단 고혈압 치료제를 이용한 흡연 및 비흡연자의 폐암 억제 방법
JP6930693B2 (ja) * 2015-12-01 2021-09-01 サン ファーマシューティカル インダストリーズ リミテッドＳｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｉｎｄｕｓｔｒｉｅｓ Ｌｔｄ． ジルチアゼムの非経口投薬形態
BR112018015444B1 (pt) * 2016-01-29 2023-12-19 Mannkind Corporation Inalador de pó seco
HU231031B1 (hu) * 2016-03-23 2019-12-30 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Megnövelt stabilitású epoprostenol nátrium és eljárás előállítására
JP6976577B2 (ja) * 2016-07-20 2021-12-08 国立大学法人東北大学 ＰＰＡＲαアゴニストを含有する、肺高血圧症の予防又は治療剤
US10799653B2 (en) 2017-01-09 2020-10-13 United Therapeutics Corporation Aerosol delivery device and method for manufacturing and operating the same
US10702495B2 (en) 2017-02-20 2020-07-07 Nexien Biopharma, Inc. Method and compositions for treating dystrophies and myotonia
US20210386944A1 (en) * 2018-10-12 2021-12-16 Sanotize Research Development Corp. Gas-evolving compositions and container and delivery systems
EP3750528A1 (en) 2019-06-11 2020-12-16 Nexien Biopharma, Inc. Compositions for treating dystrophies and myotonia
KR20230011929A (ko) 2020-04-17 2023-01-25 유나이티드 쎄러퓨틱스 코포레이션 간질성 폐 질환의 치료에 사용하기 위한 트레프로스티닐
WO2023178283A1 (en) 2022-03-18 2023-09-21 Epicentrx, Inc. Co-crystals of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone and methods
CN114652704A (zh) * 2022-04-29 2022-06-24 兆科药业（广州）有限公司 一种曲前列尼尔软雾吸入剂
KR20250002687A (ko) * 2022-04-29 2025-01-07 자오커 파마슈티컬 (광저우) 컴퍼니., 리미티드 트레프로스티닐 소프트 미스트 흡입제
WO2023215227A1 (en) 2022-05-02 2023-11-09 Epicentrx, Inc. Systems and methods to improve exercise tolerance
WO2023215229A1 (en) 2022-05-02 2023-11-09 Epicentrx, Inc. Compositions and methods for treatment of pulmonary hypertension
WO2023244973A1 (en) 2022-06-13 2023-12-21 Epicentrx, Inc. Compositions and methods for reducing adverse side effects in cancer treatment
CN118453510A (zh) * 2022-09-07 2024-08-09 上海交通大学医学院附属第九人民医院 一种能够预防肺动脉压急性增高的载药乙醇注射液及其制备方法与应用
WO2024098009A1 (en) 2022-11-04 2024-05-10 Epicentrx, Inc. Rrx-001 for minimizing post-infarct adverse ventricular remodeling and complications
WO2024124152A1 (en) 2022-12-08 2024-06-13 Epicentrx, Inc. Rrx-001 for the treatment of a hemoglobinopathy

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2414918A (en) 1941-09-23 1947-01-28 Abramson Harold Alexander Solutions for the improved nebulization therapy of the lungs and bronchioles
GB1114313A (en) * 1964-11-19 1968-05-22 Wyeth John & Brother Ltd Pharmaceutical compositions
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
USD275732S (en) 1982-05-21 1984-10-02 Dey Laboratories, Inc. Liquid dispensing container
CH657779A5 (de) * 1982-10-05 1986-09-30 Sandoz Ag Galenische zusammensetzungen enthaltend calcitonin.
FR2568773B1 (fr) * 1984-08-10 1989-03-03 Sandoz Lab Nouvelles compositions pharmaceutiques administrables par voie nasale
USD289609S (en) 1984-11-29 1987-05-05 Dey Laboratories, Inc. Liquid dispensing container
USD296869S (en) 1985-09-18 1988-07-26 Dey Laboratories, Inc. Liquid dispensing container
EP0579260A1 (en) * 1987-07-07 1994-01-19 Beecham Group Plc Use of a vasodilator for the treatment of pulmonary hypertension and/or right heart failure-related conditions
USD317715S (en) 1989-10-10 1991-06-25 Dey Laboratories, Inc. Liquid dispensing container
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
SE9000207L (sv) * 1990-01-22 1991-07-23 Nobel Chemicals Ab Laekemedel samt anvaendningen av detsamma
JPH0729938B2 (ja) 1990-05-11 1995-04-05 フアイザー・インコーポレイテツド 相乗的治療用組成物及び方法
US5570683A (en) 1990-12-05 1996-11-05 The General Hospital Corporation Methods and devices for treating pulmonary vasoconstriction and asthma
DE69127756T2 (de) * 1990-12-05 1998-02-05 The General Hospital Corp., Charlestown, Mass. Verwendung von no zur behandlung oder prävention der bronchokonstriktion
GB9118830D0 (en) * 1991-09-03 1991-10-16 Minnesota Mining & Mfg Medical aerosol formulations
DE4215317C2 (de) 1992-05-09 1994-04-21 Ver Glaswerke Gmbh Vorrichtung zum Beschichten einer Oberfläche einer Glasscheibe
US5376666A (en) * 1992-11-30 1994-12-27 The Du Pont Merck Pharmaceutical Company Angiotension-II receptor blocking, azacycloalkyl or azacycloalkenyl
US20020132787A1 (en) * 1993-04-07 2002-09-19 Mohammed Eljamal Compositions and methods for nucleic acid delivery to the lung
GB9310713D0 (en) 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
JPH0753358A (ja) * 1993-08-17 1995-02-28 Teijin Ltd 吸入剤
US5728705A (en) * 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
GB9410222D0 (en) 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
DE4435422A1 (de) 1994-10-04 1996-04-18 Basf Ag Verfahren zur Herstellung einer wäßrigen Polymerisatdispersion
GB9601202D0 (en) 1996-01-22 1996-03-20 Pfizer Ltd Piperidones
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
WO1998042368A1 (en) * 1997-03-20 1998-10-01 Novo Nordisk A/S Therapeutic powder formulation for pulmonary administration, containing crystalline insulin
US6214873B1 (en) * 1997-04-04 2001-04-10 Welfide Corporation 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
US5980882A (en) * 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
US6187765B1 (en) * 1997-10-09 2001-02-13 Schering Corporation Mometasone furoate suspensions for nebulization
US6541479B1 (en) * 1997-12-02 2003-04-01 Massachusetts College Of Pharmacy Calcium channel blockers
RU2161483C2 (ru) 1998-02-04 2001-01-10 Мурина Марина Алексеевна Средство для угнетения активности тромбоцитов
US20020086852A1 (en) 1998-05-14 2002-07-04 Cantor Jerome O. Method for treating respiratory disorders associated with pulmonary elastic fiber injury
AU4841799A (en) * 1998-06-29 2000-01-17 Nastech Pharmaceutical Company, Inc Methods and pharmaceutical formulations for preventing and treating motion sickness
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US6121300A (en) 1998-11-10 2000-09-19 Wagle; Dilip R. Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts
JP2002529393A (ja) 1998-11-12 2002-09-10 フランク ジー． ピルキーウィッツ， 吸入システム
GB9826941D0 (en) 1998-12-09 1999-02-03 Zeneca Pharmaceuticals Compounds
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
IT1313553B1 (it) * 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
IT1317904B1 (it) * 1999-09-11 2003-07-15 Glaxo Group Ltd Formulazione farmaceutica di propionato di fluticasone.
US6174906B1 (en) * 1999-10-01 2001-01-16 Smithkline Beecham Corporation Endothelin receptor antagonists
PE20010720A1 (es) * 1999-12-11 2001-07-26 Glaxo Group Ltd Distribuidor de medicamento
US20010031738A1 (en) * 2000-01-19 2001-10-18 Schwarz Margaret A. Methods and pharmaceutical formulations for the treatment of pulmonary hypertension and methods for screening compounds useful in the treatment of pulmonary hypertension
US20030103983A1 (en) * 2002-05-09 2003-06-05 Pressler Milton Lethan Ace inhibitor-vasopressin antagonist combinations
ES2272341T3 (es) 2000-01-26 2007-05-01 Astellas Pharma Inc. Combinaciones de inhibidores de enzima y de antagonistas.
US6723702B2 (en) * 2000-02-09 2004-04-20 Ras Medical, Inc. Use of relaxin treat diseases related to vasoconstriction
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
JP3691341B2 (ja) * 2000-05-16 2005-09-07 日新製鋼株式会社 精密打抜き性に優れたオーステナイト系ステンレス鋼板
GB0014883D0 (en) 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0020691D0 (en) * 2000-08-22 2000-10-11 Boehringer Ingelheim Pharma Pharmaceutical combination
US20020142970A1 (en) 2000-10-10 2002-10-03 Vaughan Douglas E. Method for treating or preventing cardiovascular disease via administration of an ace inhibitor
DE10062712A1 (de) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
ES2203601T3 (es) 2000-10-31 2004-04-16 Debiopharm S.A. Suspension de una proteina de epi-hne, metodo para su preparacion, un aerosol en forma de polvo seco derivado de la misma, compuestos farmaceuticos que comprenden dicha suspension o dicho aerosol y sus utilizaciones.
DE10113366A1 (de) * 2001-03-20 2002-09-26 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Endothelinantagonisten
US6608054B2 (en) * 2001-03-20 2003-08-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and endothelin antagonists
AU2002241538A1 (en) 2000-12-01 2002-07-24 Nephros Therapeutics, Inc. Intrasvascular drug delivery device and use therefor
US20040048905A1 (en) * 2000-12-18 2004-03-11 Daley William Lionel Therapeutic combination of amlodipine and benazepril
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
WO2002094237A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of beta-blockers through an inhalation route
US20030078190A1 (en) * 2001-05-25 2003-04-24 Weinberg Marc S. Methods for tissue protection using highly effective inhibition of the renin-angiotensin system
AU2002355419A1 (en) 2001-08-06 2003-02-24 Genomed, Llc Methods and compositions for treating diseases associated with excesses in ace
US6939534B2 (en) 2001-08-13 2005-09-06 Genomed, Llc Method to treat pulmonary hypoplasia in the newborn
US7040313B2 (en) 2001-09-05 2006-05-09 Cyterra Corporation Method and apparatus for nitric oxide generation
FR2831446B1 (fr) 2001-10-26 2004-03-05 Sanofi Synthelabo Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire
DE10214983A1 (de) * 2002-04-04 2004-04-08 TransMIT Gesellschaft für Technologietransfer mbH Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen
TWI299663B (en) * 2002-05-14 2008-08-11 Novartis Ag Methods of treatment
WO2004047837A2 (en) * 2002-11-22 2004-06-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-blockers having antioxidant and nitric oxide-donor activity
US20050119330A1 (en) * 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
US20040265238A1 (en) 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20070117861A1 (en) * 2003-11-12 2007-05-24 University Of South Carolina Treatment or prevention of cardiovascular and respiratory disorders with novel substituted cyclic-amp specific phosphodiesterase inhibitors
US20050191245A1 (en) * 2004-02-27 2005-09-01 Adams Christopher P. Nasal administration of calcium channel, blockers for treatment of hypertension and other cardiovascular disorders
US20110207555A1 (en) * 2010-02-24 2011-08-25 Bridgestone Sports Co., Ltd. Multiple-piece golf ball

Also Published As

Publication number Publication date
JP5571867B2 (ja) 2014-08-13
MXPA05013539A (es) 2006-03-09
CN1822817B (zh) 2012-10-10
WO2005000270A2 (en) 2005-01-06
RU2006102206A (ru) 2006-08-27
JP2012001549A (ja) 2012-01-05
CA2530632A1 (en) 2005-01-06
KR20060026070A (ko) 2006-03-22
CN1822817A (zh) 2006-08-23
KR20140141728A (ko) 2014-12-10
PL1638525T3 (pl) 2012-10-31
ATE548025T1 (de) 2012-03-15
JP2007519604A (ja) 2007-07-19
JP2014240443A (ja) 2014-12-25
US20040265238A1 (en) 2004-12-30
BRPI0411904B8 (pt) 2021-05-25
AU2004251014B8 (en) 2011-02-10
ZA200600773B (en) 2007-05-30
AU2011200464A1 (en) 2011-02-24
WO2005000270A3 (en) 2005-05-12
EP1638525B1 (en) 2012-03-07
RU2010152753A (ru) 2012-06-27
AU2004251014A1 (en) 2005-01-06
JP6141811B2 (ja) 2017-06-07
AU2011200464B2 (en) 2012-08-09
JP5981109B2 (ja) 2016-08-31
AU2004251014B2 (en) 2010-11-25
US9498437B2 (en) 2016-11-22
US20060104913A1 (en) 2006-05-18
RU2491072C2 (ru) 2013-08-27
BRPI0411904A (pt) 2006-08-08
CA2530632C (en) 2012-03-06
EP1638525A2 (en) 2006-03-29
BRPI0411904B1 (pt) 2020-11-03
US20110265786A1 (en) 2011-11-03
ES2384384T3 (es) 2012-07-04
KR101824298B1 (ko) 2018-01-31
KR20120068052A (ko) 2012-06-26

Similar Documents

Publication Publication Date Title
HK1093017A1 (en) Inhalable formulations for treating pulmonary hypertension and methods of using same
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
EA200400966A1 (ru) Новые лекарственные формы замещенного бензимидазола и способ их применения
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
NO20045677L (no) Inhibitorer av JAK- og CDK2-proteinkinaser
HK1096673A1 (en) Compositions useful as inhibitors of protein kinases
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
TW200604168A (en) Azaindoles useful as inhibitors of rock and other protein kinases
EP1059100A3 (en) Combinations of CRF antagonists and renin-angiotensin system inhibitors
TW200633980A (en) Pyridones useful as inhibitors of kinases
WO2005107747A3 (en) Diindolymethane formulations for the treatment of leiomyomas
HK1104544A1 (en) Quinazolines useful as modulators of ion channels
EP1534270A4 (en) CARVEDILOL PHOSPHATE SALTS AND / OR ITS SOLVENTS, CORRESPONDING COMPOSITIONS AND / OR TREATMENT PROCEDURES
WO2002060392A3 (en) Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
WO2006078503A3 (en) Compositions for modulation of parp and methods for screening for same
NO20080697L (no) Modifiserte farmasoytiske doseringsformer for frigivelse av syklooksygenase enzyminhibitor
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
MXPA03007413A (es) Composicion y metodo para tratar enfermedades inflamatorias.
WO2006052899A3 (en) Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
EA200300850A1 (ru) Применение антагонистов рецептора gal3 при лечении депрессии и/или тревоги и соединения, полезные в таких способах
WO2004014307A3 (en) Gal3 antagonists for the treatment of neuropathic pain

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20240613